158 related articles for article (PubMed ID: 19797313)
1. A murine model of Denys-Drash syndrome reveals novel transcriptional targets of WT1 in podocytes.
Ratelade J; Arrondel C; Hamard G; Garbay S; Harvey S; Biebuyck N; Schulz H; Hastie N; Pontoglio M; Gubler MC; Antignac C; Heidet L
Hum Mol Genet; 2010 Jan; 19(1):1-15. PubMed ID: 19797313
[TBL] [Abstract][Full Text] [Related]
2. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
[TBL] [Abstract][Full Text] [Related]
3. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.
Schumacher VA; Jeruschke S; Eitner F; Becker JU; Pitschke G; Ince Y; Miner JH; Leuschner I; Engers R; Everding AS; Bulla M; Royer-Pokora B
J Am Soc Nephrol; 2007 Mar; 18(3):719-29. PubMed ID: 17267748
[TBL] [Abstract][Full Text] [Related]
4. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
Yang Y; Jeanpierre C; Dressler GR; Lacoste M; Niaudet P; Gubler MC
Am J Pathol; 1999 Jan; 154(1):181-92. PubMed ID: 9916932
[TBL] [Abstract][Full Text] [Related]
5. A proteomic investigation of glomerular podocytes from a Denys-Drash syndrome patient with a mutation in the Wilms tumour suppressor gene WT1.
Viney RL; Morrison AA; van den Heuvel LP; Ni L; Mathieson PW; Saleem MA; Ladomery MR
Proteomics; 2007 Mar; 7(5):804-15. PubMed ID: 17295355
[TBL] [Abstract][Full Text] [Related]
6. A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development.
Natoli TA; Liu J; Eremina V; Hodgens K; Li C; Hamano Y; Mundel P; Kalluri R; Miner JH; Quaggin SE; Kreidberg JA
J Am Soc Nephrol; 2002 Aug; 13(8):2058-67. PubMed ID: 12138137
[TBL] [Abstract][Full Text] [Related]
7. Glomerular epithelial cell phenotype in diffuse mesangial sclerosis: a report of 2 cases with markedly increased urinary podocyte excretion.
Ikezumi Y; Suzuki T; Karasawa T; Kaneko U; Yamada T; Hasegawa H; Nagata M; Saitoh A
Hum Pathol; 2014 Aug; 45(8):1778-83. PubMed ID: 24856573
[TBL] [Abstract][Full Text] [Related]
8. Integration of Cistromic and Transcriptomic Analyses Identifies Nphs2, Mafb, and Magi2 as Wilms' Tumor 1 Target Genes in Podocyte Differentiation and Maintenance.
Dong L; Pietsch S; Tan Z; Perner B; Sierig R; Kruspe D; Groth M; Witzgall R; Gröne HJ; Platzer M; Englert C
J Am Soc Nephrol; 2015 Sep; 26(9):2118-28. PubMed ID: 25556170
[TBL] [Abstract][Full Text] [Related]
9. Repression of CMIP transcription by WT1 is relevant to podocyte health.
Moktefi A; Zhang SY; Vachin P; Ory V; Henique C; Audard V; Rucker-Martin C; Gouadon E; Eccles M; Schedl A; Heidet L; Ollero M; Sahali D; Pawlak A
Kidney Int; 2016 Dec; 90(6):1298-1311. PubMed ID: 27650733
[TBL] [Abstract][Full Text] [Related]
10. New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes.
Morrison AA; Viney RL; Saleem MA; Ladomery MR
Am J Physiol Renal Physiol; 2008 Jul; 295(1):F12-7. PubMed ID: 18385267
[TBL] [Abstract][Full Text] [Related]
11. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis.
Guo JK; Menke AL; Gubler MC; Clarke AR; Harrison D; Hammes A; Hastie ND; Schedl A
Hum Mol Genet; 2002 Mar; 11(6):651-9. PubMed ID: 11912180
[TBL] [Abstract][Full Text] [Related]
12. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.
Palmer RE; Kotsianti A; Cadman B; Boyd T; Gerald W; Haber DA
Curr Biol; 2001 Nov; 11(22):1805-9. PubMed ID: 11719225
[TBL] [Abstract][Full Text] [Related]
13. WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier.
Schumacher VA; Schlötzer-Schrehardt U; Karumanchi SA; Shi X; Zaia J; Jeruschke S; Zhang D; Pavenstädt H; Drenckhan A; Amann K; Ng C; Hartwig S; Ng KH; Ho J; Kreidberg JA; Taglienti M; Royer-Pokora B; Ai X
J Am Soc Nephrol; 2011 Jul; 22(7):1286-96. PubMed ID: 21719793
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta1 reduces Wilms' tumor suppressor gene expression in podocytes.
Sakairi T; Abe Y; Kopp JB
Nephrol Dial Transplant; 2011 Sep; 26(9):2746-52. PubMed ID: 21378152
[TBL] [Abstract][Full Text] [Related]
15. Activation of podocyte Notch mediates early Wt1 glomerulopathy.
Asfahani RI; Tahoun MM; Miller-Hodges EV; Bellerby J; Virasami AK; Sampson RD; Moulding D; Sebire NJ; Hohenstein P; Scambler PJ; Waters AM
Kidney Int; 2018 Apr; 93(4):903-920. PubMed ID: 29398135
[TBL] [Abstract][Full Text] [Related]
16. The dysregulated glomerular cell growth in Denys-Drash syndrome.
Yang AH; Chen JY; Chen BF
Virchows Arch; 2004 Sep; 445(3):305-14. PubMed ID: 15232745
[TBL] [Abstract][Full Text] [Related]
17. A novel WT1 gene mutation in a three-generation family with progressive isolated focal segmental glomerulosclerosis.
Benetti E; Caridi G; Malaventura C; Dagnino M; Leonardi E; Artifoni L; Ghiggeri GM; Tosatto SC; Murer L
Clin J Am Soc Nephrol; 2010 Apr; 5(4):698-702. PubMed ID: 20150449
[TBL] [Abstract][Full Text] [Related]
18. Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome.
Swiatecka-Urban A; Mokrzycki MH; Kaskel F; Da Silva F; Denamur E
Pediatr Nephrol; 2001 Aug; 16(8):627-30. PubMed ID: 11519891
[TBL] [Abstract][Full Text] [Related]
19. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
[TBL] [Abstract][Full Text] [Related]
20. Clinical Aspects of WT1 and the Kidney.
Miller-Hodges E
Methods Mol Biol; 2016; 1467():15-21. PubMed ID: 27417956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
